



## Figures - Key Numbers

Ticker: (NASDAQ: PIRS)  
 Share price: \$7.55 (as of 12/29/17)  
 Market Cap: \$338.2M (as of 12/29/2017)  
 Revenue: \$5.8M (FY2016)  
 Net Loss: \$22.8M (FY2016)  
 Cash: \$89.9M (as of 9/30/17)

## Corporate Headquarters

Pieris Pharmaceuticals, Inc.  
 255 State Street, 9<sup>th</sup> floor  
 Boston, MA 02109  
 +1 (857) 246 8998

## Munich Site

Pieris Pharmaceuticals GmbH  
 Lise-Meitner-Strasse 30  
 85354 Freising  
 Germany  
 +49 (0) 8161 1411 400

For more information:

[info@pieris.com](mailto:info@pieris.com)

[www.pieris.com](http://www.pieris.com)

For business development or partnering inquiries, please contact Eckhard Niemeier, VP BD: [niemeier@pieris.com](mailto:niemeier@pieris.com)

For investor relations inquiries, please contact Thomas Hoffman at The Trout Group, LLC: [thoffman@troutgroup.com](mailto:thoffman@troutgroup.com)

## Company Overview


Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin®-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics (tumor-targeted costimulatory approach and dual-checkpoint inhibitors), inhaled Anticalin proteins to treat respiratory diseases and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is registered trademark of Pieris.

## Pieris Strategy

- Advance its lead IO program, PRS-343 (HER2/4-1BB), through first-in patient trials in 2017/18 and further develop its immuno-oncology franchise
- Advance its lead Asthma program PRS-060 (IL4Ra) into clinical trials in 2017 and strengthen its respiratory franchise for inhaled biologics
- Advance its anemia program PRS-080 (hepcidin) through first-in patient trials in 2017/18
- Continue to exploit its platform through new and existing partnerships

## Anticalin Proteins

Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can bind to virtually any target of interest.



## Differentiation from Antibodies

- Formatting flexibility for multispecific drugs
- Alternative delivery routes (e.g. inhaled)
- Cheaper, bacterial expression
- Tunable kinetics to match biological need
- Dominant patent position and positive FTO position

## Management Team

Stephen S. Yoder, President & Chief Executive Officer  
 Louis Matis, MD, SVP & Chief Development Officer  
 Allan Reine, MD, SVP & Chief Financial Officer  
 Shane Olwill, PhD, VP, Development & Head of Immuno-Oncology  
 Christine Rothe, PhD, VP, Head of Discovery & Alliance Management  
 Mary Fitzgerald, PhD, VP, Respiratory Medicine  
 Eckhard Niemeier, VP, Business Development  
 Ahmed Mousa, VP, Licensing, IP & Legal Affairs  
 Ingmar Bruns, MD, PhD, VP, Clinical Development  
 Tom Bures, VP, Finance  
 Frank Vollmering, VP, Talent & Organizational Development

## Board of Directors

James Geraghty (Former Executive, Sanofi and Genzyme), Chairman  
 Jean-Pierre Bizzari, MD (Former EVP, Celgene)  
 Steven Prelack (SVP & COO, VetCor)  
 Michael Richman (CEO, NextCure)  
 Julian Adams, Ph.D (CEO, Gamida Cell)  
 Christopher Kiritsy (President, Arisaph Pharmaceuticals)  
 Stephen S. Yoder (President & CEO, Pieris)



**May 2017:** Multi-program strategic co-development alliance to develop inhaled biologics for respiratory diseases. Includes PRS-060 and 4 additional programs



**January 2017:** Multi-program strategic co-development immuno-oncology alliance. Includes PRS-332 and 4 additional programs



**February 2017:** Option on anemia program PRS-080 in Japan and other Asian countries



**December 2015:** Discovery and development of Anticalin therapeutics in immuno-oncology



**October 2013:** Co-development of novel Anticalin therapeutics, including cMet



**April 2011:** Discovery and development partnership on novel Anticalin therapeutics



**September 2010:** Multi-target collaboration with both Sanofi and Sanofi Pasteur across a broad spectrum of indications

## IMMUNO-ONCOLOGY PROGRAMS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND-enabling	Phase I	Phase Ib/IIa
PRS-343	4-1BB/HER2 Bispecific	IO		Worldwide					
PRS-342	4-1BB/GPC3 Bispecific	IO		Worldwide					
PRS-300s	n.d.	IO		Worldwide					
PRS-332	PD-1/n.d. Bispecific	IO		U.S.					
Servier 4 Programs	n.d./n.d. Bispecific	IO		U.S. for 2 bispecifics					
Roche	n.d.	IO		Milestones & Royalties					

## RESPIRATORY PROGRAMS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND-enabling	Phase I	Phase Ib/IIa
PRS-060	IL4Ra	Asthma		U.S. co-commercialization					
AstraZeneca 4 Programs	n.d.	Respiratory Diseases		U.S. co-commercialization for 2 targets					

## ANEMIA AND OTHER DISEASE AREAS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND-enabling	Phase I	Phase Ib/IIa
PRS-080	Hepcidin	Anemia		Major Markets ex-Japan					
Daiichi Sankyo	n.d.	n.d.		Milestones & Royalties					
Sanofi	<i>P. aeruginosa</i>	Infectious disease		Milestones & Royalties					
PRS-110	cMet	Oncology		Major Markets					

### Potential 2017 Milestones:

- ✓ Preclinical and clinical progression of ongoing programs
- ✓ First-in-Patient trial with PRS-343 (IO)
- First-in-Man trial for PRS-060 (asthma)
- ✓ Data from multispecifics IO platform
- ✓ First patient data for PRS-080 (anemia)
  - ✓ Phase 1b (single dose) in H1 2017
  - ✓ Start Phase 2a (multi-dose) in H2 2017
- ✓ Additional collaborations

### Program Highlights

#### PRS-080 - Anemia

- Lead program against hepcidin
- Targets anemia in CKD and cancer
- Tuned kinetics to address target biology
- Phase 1b trial in CKD hemodialysis (HD) patients – completed successfully
- Phase 2a trial in CKD HD patients started in H2 2017
- ASKA Pharmaceutical with option for Japan

#### PRS-060 – Respiratory Diseases

- Preclinical program against IL4Ra
- Targets asthma and other respiratory diseases
- Differentiates from antibodies against IL-4 and IL-13 through inhaled delivery directly into the lungs, contrasted with s.c. mAbs
- Local delivery is more convenient for patients and allows for low doses, potentially resulting in a significant cost of goods advantage and expanded patient population over systemic mAbs
- PRS-060 is being developed in a collaboration with AstraZeneca

#### PRS-343 – (4-1BB/HER2 bispecific)

- Bispecific drug candidate with a 4-1BB-targeting Anticalin (key costimulatory target for tumor-specific T cells) and a HER2-targeting mAb (validated expression in bladder, gastric, breast cancer, etc.)
- PRS-343 has demonstrated strong tumor growth inhibition and lymphocyte infiltration *in vivo*, while avoiding undesirable peripheral T cell activation
- First patient dosed in Phase 1 trial

#### PRS-332 – (PD-1 / undisclosed checkpoint)

- Bispecific program combining an Anticalin against an undisclosed key checkpoint target with an anti-PD-1 mAb
- PRS-332 is being co-developed with Servier where Pieris retains full U.S. commercial rights

#### Pieris Immuno-Oncology Strategy

- Engage immune costimulatory targets in a highly novel, targeted manner with unique multispecifics, led by PRS-343
- Simultaneously block multiple immune checkpoints in one drug built on key backbone components (e.g. PD-1), led by PRS-332
- Demonstrate intra-pipeline synergy between targeted costimulatory engagement and multi-checkpoint blockade within own pipeline